

**SAMPLE PHYSICIAN APPEAL LETTER**  
**FOR PROMETHEUS® Serum Infliximab/HACA Measurement**

*(Please edit appropriately based on your patient's medical history and treatment experience.)*

<DATE>

John Smith, Medical Director  
Red Cross Red Shield  
P.O. Box 12345  
Los Angeles, CA 90060

Dear Dr. Smith:

I am writing to appeal your decision about medical coverage for the PROMETHEUS® Serum Infliximab/HACA Measurement testing for my patient, Jane Doe. I am Ms. Doe's gastroenterologist practicing at Sunnyvale Community Hospital in San Diego, CA. I respectfully request that you reconsider your decision based on the medical necessity of this test for the assistance with therapeutic decisions.

**PATIENT INFORMATION**

My patient is receiving Infliximab infusions.

***(List information relevant to the patient's symptoms, treatment and test results if applicable)***

Patient: Jane Doe  
ID: XXX123456789  
Provider: Ulysses Grant, MD  
Claim #: 111111  
Date of service: July 4, 2005  
Original Claim: \$225.00  
Date of EOB: December 31, 2005  
Explanation of Benefits (EOB):

1. Out-of-network deductibles/rates applied
  2. Laboratory services available through a capitated laboratory
  3. Laboratory testing not considered medically necessary
- (List information provided on the patient's insurance EOB)***

**TEST DESCRIPTION**

Serum infliximab concentrations may vary among equally dosed patients. PROMETHEUS® Serum Infliximab/HACA Measurement can aid physicians in determining the dose of infliximab and guide infusion intervals. The HACA portion of the test detects Human Anti-Chimeric Antibodies (antibodies against infliximab). Patients that develop HACA may experience infusion reactions and/or a reduced duration of efficacy of infliximab.

PROMETHEUS® Serum Infliximab/HACA Measurement is offered only at Prometheus Laboratories Inc., a clinical reference laboratory in San Diego, California. Prometheus is CLIA certified and CAP accredited. All laboratory tests have been validated in accordance with the guidelines established by these and other applicable agencies. Currently, Food and Drug Administration (FDA) approval is not required for testing performed by Prometheus.

## **NETWORK PROVIDER SERVICES**

I chose Prometheus to perform PROMETHEUS® Serum Infliximab/HACA Measurement instead of alternative in-network laboratory testing because of the information provided on their comprehensive report. There is no in-network laboratory in my area willing to refer the test or able to provide comparable testing.

### **>AND/OR<**

I ordered the test and directed my patient to an in-network laboratory which does not offer PROMETHEUS® Serum Infliximab/HACA Measurement. I have made a good-faith attempt to follow insurance guidelines and was unaware of the referral to an out-of-network provider.

## **LABORATORY AND PHYSICIAN INFORMATION**

For additional information about PROMETHEUS® Serum Infliximab/HACA Measurement contact Prometheus Laboratories Inc. at 1-888-423-5227. If you require additional medical information, please feel free to contact me at XXX-XXX-XXXX

## **REFERENCE MATERIALS**

- St. Clair EW et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. *Arthritis and Rheumatism*. 2002;46(6):1451-1459.
- Baert F et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. *The New England Journal of Medicine*. 2003;348:601-608.

Please approve full coverage for PROMETHEUS® Serum Infliximab/HACA Measurement or at least apply in-network benefit coverage for this test.

Thank you for your prompt attention. I look forward to receiving a written response from you within two weeks.

Sincerely,

Ulysses Grant, MD  
Sunnyvale Community Hospital  
12345 Sunnyvale Road  
San Diego, CA 92121  
XXX-XXX-XXXX